(Q38439307)

3 September 2017

title

Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials (English)

1 reference

3 September 2017

1 reference

1

Cristina Sampaio

1 reference

3 September 2017

5

Olivier Rascol

1 reference

3 September 2017

4

Anthony E Lang

1 reference

3 September 2017

3

Robert A Hauser

1 reference

3 September 2017

2

Juliana Bronzova

1 reference

3 September 2017

6

Serge V van de Witte

1 reference

3 September 2017

And Ad Theeuwes

7

1 reference

3 September 2017

Rembrandt/Vermeer Study Groups

series ordinal

8

1 reference

3 September 2017

language of work or name

English

0 references

publication date

3 May 2011

1 reference

3 September 2017

1 reference

3 September 2017

volume

26

1 reference

3 September 2017

issue

8

1 reference

3 September 2017

page(s)

1464-1476

1 reference

Etiology and pathogenesis of Parkinson's disease

3 September 2017

cites work

1 reference

Limitations of current Parkinson's disease therapy

21 January 2018

1 reference

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

21 January 2018

1 reference

Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.

21 January 2018

1 reference

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

21 January 2018

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa

21 January 2018

1 reference

Antagonist effect of terguride in Parkinson's disease

21 January 2018

1 reference

In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist

21 January 2018

1 reference

Quality of life and depression in Parkinson's disease

21 January 2018

1 reference

21 January 2018

Transdermal Rotigotine

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.23590

1 reference

3 September 2017

1 reference